Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Theravance Reports Positive Phase II Results For Chronic Constipation Therapy TD-5108

This article was originally published in The Pink Sheet Daily

Executive Summary

Specificity of the 5-HT4 agonist gives it a better cardiovascular safety profile than withdrawn Novartis product Zelnorm, Theravance VP-Development Kitt says.
Advertisement

Related Content

GlaxoSmithKline Declines To License Theravance GI Motility Drug At Brink Of Phase III
GlaxoSmithKline Declines To License Theravance GI Motility Drug At Brink Of Phase III
Zelnorm Will Be Available Under Treatment IND Following Marketing Suspension
Zelnorm Will Be Available Under Treatment IND Following Marketing Suspension
Theravance’s First NDA Is Antibiotic Telavancin

Topics

Advertisement
UsernamePublicRestriction

Register

PS066239

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel